TICKERNERD
Menu
ARMPARMPHealthcare · Biotechnology

ARMP Stock Forecast: Armata Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 9 Oct 2026
$3.63
−5.96% on the day

The 2 Wall Street analysts covering Armata Pharmaceuticals, Inc. hold a median 12-month price target of $18 — +382.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 8 Oct 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$143.5M
Ticker Nerd rank
74 / 100
Median analyst target
$18
Analysts covering
2
Revenue$0.0
Operating income−$8.8M
Net income−$115.3M
Free cash flow−$5.8M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.1%
1M
−32.9%
YTD
−42.2%
1Y
+13.1%
From 52W high
−75.5%
From 52W low
+14.5%
$3
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ARMP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Armata Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
74 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
95
Value
84
Momentum
81
Size
71
Revisions
64
Volatility
62
Quality
50
Growth
27
Issuance
15

Accruals (95): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (15): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ARMP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARMP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Jan 26Apr 26Jul 26Oct 26ARMPHigh $20Median $18Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $15Median $18High $20

The green dot is the last close — the median target sits +382.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 Sept 2026HC Wainwright & Co.ReiteratesBuy—
23 Feb 2026HC Wainwright & Co.MaintainsBuy—
5 Jan 2026Jones TradingInitiatesBuy—
19 May 2025HC Wainwright & Co.MaintainsBuy—
19 Dec 2024HC Wainwright & Co.ReiteratesBuy—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
12 Nov 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
11 July 2024HC Wainwright & Co.ReiteratesBuy—
8 May 2024HC Wainwright & Co.ReiteratesBuy—
22 Mar 2024HC Wainwright & Co.MaintainsBuy—
14 Aug 2023HC Wainwright & Co.ReiteratesBuy—
12 May 2023HC Wainwright & Co.ReiteratesBuy—
17 Mar 2023HC Wainwright & Co.ReiteratesBuy—
7 Mar 2023HC Wainwright & Co.ReiteratesBuy—
22 Mar 2021HC Wainwright & Co.MaintainsBuy—
15 May 2020H.C. WainwrightReiteratesBuy—
15 May 2020HC Wainwright & Co.ReiteratesBuy—
20 Mar 2020H.C. WainwrightReiteratesBuy—
20 Mar 2020HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARMP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ARMP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 9 Oct 2026, Armata Pharmaceuticals, Inc. returned +13.1% against +16.6% for the S&P 500, dividends included.

ARMP vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400Jan 26Apr 26Jul 26Oct 26ARMPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ARMP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Armata Pharmaceuticals, Inc. (ARMP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.8×

Cheaper than 82% of US stocks

Price / sales
25.8×

Cheaper than 8% of US stocks

Price / book
−0.4×

Cheaper than 94% of US stocks

EV / EBITDA
−13.0×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
15.7%

Higher than 63% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−410.8%

Higher than 8% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
79.5%

Higher than 95% of US stocks

Return on assets
−25.8%

Higher than 16% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Armata Pharmaceuticals, Inc. (ARMP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Armata Pharmaceuticals, Inc. has a market value of $143.5M and an enterprise value of $433.5M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0. The latest quarter grew 15.7% year on year.

  • Net income over the same four quarters: −$282.6M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$24.5M, after $506K of capital spending.

  • Shares outstanding: 37.2M.

  • Trailing P/E: −0.8×; forward P/E: −1.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Armata Pharmaceuticals, Inc. employs 61 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

ARMP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARMPArmata Pharmaceuticals, Inc.$143.5M
74
RNAAtrium Therapeutics, Inc.$141.4M
5
VYGRVoyager Therapeutics, Inc.$141.3M
76
AVXLAnavex Life Sciences Corp.$142.7M
24
TLSATiziana Life Sciences Ltd. (Bermuda)$145.0M
18
OTLKOutlook Therapeutics, Inc.$137.3M
5
CDXSCodexis, Inc.$146.3M
62

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Armata Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ARMP news & analysis

Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States

PRNewsWire · 7 Oct 2026positive

Armata Pharmaceuticals announced that the USPTO issued two patents covering its AP-SA02 and AP-PA02 bacteriophage programs. The company said the patents provide intellectual property protection for the clinical candidates until at least 2041.

Why it matters — The issuances strengthen intellectual property protection around two of Armata’s clinical-stage candidates.

Armata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial Program

Benzinga · 23 Sept 2026neutral

Armata Pharmaceuticals shares traded lower on Wednesday as investors weighed additional non-dilutive funding tied to its lead bacteriophage program. The funding supports a Phase 3 push for the company's anti-bacterial program.

Why it matters — ARMP watchers would care because the new funding supports advancement of the company's lead bacteriophage program toward a Phase 3 trial without adding dilution.

Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development

PRNewsWire · 23 Sept 2026positive

Armata Pharmaceuticals announced it received an additional $3.7 million in non-dilutive funding from the U.S. Department of War to support the Phase 3 development program for its candidate AP-SA02. This commitment is incremental to prior funding, bringing total non-dilutive support for the AP-SA02 program to $32.4 million.

Why it matters — This additional non-dilutive funding expands financial support for the AP-SA02 Phase 3 program while avoiding share dilution, which is relevant to Armata shareholders and watchers of its clinical pipeline.

Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates

PRNewsWire · 21 Sept 2026positive

Armata Pharmaceuticals announced an oral presentation at the 20th International Symposium on Staphylococci and Staphylococcal Infections (ISSSI 2026), scheduled for Monday, Sept. 21, 2026. The presentation will show that controlled manufacturing reproducibly maintains defined genetic diversity across AP-SA02 clinical drug product lots, and that this diversity may enhance killing of certain Staphylococcus aureus clinical isolates.

Why it matters — This is relevant for ARMP watchers because it provides new clinical data supporting the mechanism and manufacturing consistency of its staphylococcal phage candidate AP-SA02, which is central to its development pipeline.

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

PRNewsWire · 14 Sept 2026positive

The U.S. FDA granted Breakthrough Therapy designation to Armata Pharmaceuticals' AP-SA02, an intravenously administered bacteriophage therapy for Staphylococcus aureus bacteremia. The designation, driven by compelling Phase 2 clinical data suggesting substantial improvement over available therapies, adds to AP-SA02's existing Fast Track and QIDP designations.

Why it matters — The Breakthrough Therapy designation provides strong regulatory validation and may accelerate AP-SA02's path to market, strengthening Armata's late-stage antibacterial pipeline.

FAQ

Frequently asked questions about ARMP stock

What is the ARMP stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Armata Pharmaceuticals, Inc. have a median 12-month price target of $18, with estimates ranging from $15 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ARMP stock a buy right now?

Of the 2 analysts covering Armata Pharmaceuticals, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Armata Pharmaceuticals, Inc. 74 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARMP?

As at 8 Oct 2026, Armata Pharmaceuticals, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (95 of 100).

Will ARMP stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +382.1% from the last close, and Ticker Nerd's factor model ranks Armata Pharmaceuticals, Inc. 74 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ARMP stock forecast for 2030?

No analyst covering Armata Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARMP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $20 over the next 12 months.

How has ARMP stock performed over the past year?

Armata Pharmaceuticals, Inc. returned +13.1% over the 12 months to 9 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Armata Pharmaceuticals, Inc. do?

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections.

What is the latest news on ARMP?

The most recent item we track (PRNewsWire, 7 Oct 2026): "Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States". Armata Pharmaceuticals announced that the USPTO issued two patents covering its AP-SA02 and AP-PA02 bacteriophage programs. The company said the patents provide intellectual property protection for the clinical candidates until at least 2041.

Company

About Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. The company’s current work centers on phage-based medicines designed to target specific bacterial pathogens, with programs addressing infections such as Staphylococcus aureus bacteremia and Pseudomonas aeruginosa-related disease. Its platform combines natural and synthetic bacteriophages with proprietary engineering, microbiological surveillance, and drug development capabilities to support product design, manufacturing, and clinical testing. Armata Pharmaceuticals operates as a specialist in infectious disease therapeutics, serving an important role in the broader biopharmaceutical market by advancing alternative approaches to conventional antibiotics.

CEO Dr. Deborah L. Birx M.D. · 61 employees · United States · https://www.armatapharma.com